HitGen, Inc. Hits Day Low at CNY 27.41 Amid Price Pressure

HitGen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 7.49% on June 1, 2026, reaching an intraday low of CNY 27.41. This performance comes amid a broader market context where the China Shanghai Composite index saw a modest decrease of 0.27% on the same day. Over the past week, HitGen's stock has faced a more significant downturn, with a 13.23% drop, contrasting with the 2.28% decline of the Shanghai Composite. Despite these recent challenges, the company has demonstrated strong long-term performance, boasting a 64.23% increase over the past year, significantly outpacing the index's 21.22% growth. Financial metrics indicate that HitGen has achieved a remarkable net profit growth of 114.98% and a pre-tax profit increase of 150.73%. The company also reported its highest operating cash flow at CNY 204.8 million, reflecting robust operational efficiency. With a market capitalization of CNY 11,980 million, HitGen remains a significant entity in its industry, despite the recent fluctuations in its stock performance.